Beau’s Lines and Leukonychia in a COVID-19 Patient

Satoshi Ide\textsuperscript{1,2}, Shinichiro Morioka\textsuperscript{1,2}, Makoto Inada\textsuperscript{1} and Norio Ohmagari\textsuperscript{1,2}

Key words: Beau’s lines, leukonychia, COVID-19

A previously healthy 68-year-old Japanese man working in a fish market presented with fever and dyspnea at our hospital. He was then hospitalized after having been diagnosed with coronavirus disease (COVID-19). As the patient experienced mild hypoxemia, he was administered hydroxychloroquine 400 mg/day for 7 days and methylprednisolone 0.5 mg/kg/day for 5 days. Neither malnutrition nor hypocalcemia were observed during his 18-day hospital stay. In the outpatient follow-up one month after discharge, he reported white horizontal nail striae and sunken nails (Picture), which were clinically defined as leukonychia and Beau’s lines. Periungual desquamation, which is well known as pediatric inflammatory multisystem syndrome in children (1), is one of the clinical presentations of COVID-19. Further, both Beau’s lines and leukonychia have been reported to be associated with Kawasaki disease (2). Because COVID-19 and Kawasaki disease share similar extreme inflammatory responses, nail abnormalities may also be a significant clinical presentation of COVID-19.

The authors state that they have no Conflict of Interest (COI).

References


The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).